Drug Regulations and Pharmaceutical Safety: Issues and Opportunities
A special issue of Pharmacoepidemiology (ISSN 2813-0618).
Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 523
Special Issue Editor
Special Issue Information
Dear Colleagues,
Medicine regulations are integral to ensuring pharmaceuticals' quality, safety, and efficacy and improving health outcomes. Laws impact every facet of drug delivery, from discovery and clinical trials to manufacture and patient access. Laws can curb access to medicines, regulate harmful products, standardize practices, enhance benefits, and minimize risk. To be effective, regulations need constant review, monitoring, and evaluation. Research on the impact and policy development is critical to ensuring that laws remain fit for purpose in achieving the ideal goals of equitable access to quality, safe, and effective pharmaceuticals.
Authors are invited to submit articles that intersect on aspects of pharmaceuticals and regulations. The articles may include research concerning clinical trials, registration of medicines and market authorizations, use of off-label or unlicensed pharmaceuticals, advertising, classification, and restrictions on equitable access to medicines or any other area of medicines regulations. Informing good policy and regulations through research aids regulatory governance and improved health outcomes.
Dr. Sanya Ram
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmacoepidemiology is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- clinical trials
- registration of medicines and market authorizations
- use of off-label or unlicensed pharmaceuticals
- advertising
- classification
- equitable access to medicines
- medicines regulations
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
